Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Increased by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 307.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 13,158 shares of the company’s stock after acquiring an additional 9,931 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Moderna were worth $1,402,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Ogorek Anthony Joseph NY ADV bought a new position in Moderna in the 4th quarter valued at about $27,000. Cedar Wealth Management LLC increased its stake in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares during the period. Arlington Trust Co LLC increased its stake in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares during the period. Westside Investment Management Inc. bought a new position in Moderna during the 1st quarter valued at $32,000. Finally, Rise Advisors LLC boosted its stake in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock traded down $1.25 during trading on Tuesday, reaching $121.25. The company had a trading volume of 1,751,748 shares, compared to its average volume of 4,046,165. The firm’s 50 day simple moving average is $135.25 and its two-hundred day simple moving average is $114.90. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company has a market capitalization of $46.47 billion, a PE ratio of -7.74 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same quarter last year, the firm posted $0.19 earnings per share. The company’s quarterly revenue was down 91.0% compared to the same quarter last year. Sell-side analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 255 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the transaction, the president now directly owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $122.84, for a total transaction of $1,842,600.00. Following the completion of the sale, the director now owns 2,254,015 shares in the company, valued at $276,883,202.60. The disclosure for this sale can be found here. Insiders sold 396,239 shares of company stock worth $55,286,137 over the last ninety days. Company insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MRNA. Royal Bank of Canada raised their price objective on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 3rd. Piper Sandler restated an “overweight” rating and issued a $214.00 price target on shares of Moderna in a research report on Thursday, June 27th. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. UBS Group lifted their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, Evercore ISI reaffirmed an “in-line” rating and set a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and an average target price of $134.02.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.